Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 41 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A				Phase IV				ECTCL1 NCT00221039
	Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma				Phase III, Phase II				CLBH589B2201 NCT00425555
	Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma				Phase III, Phase II				CLBH589B2212 NCT00490776
	Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome				Phase III				Hx-CD4-110 NCT00127881
	Biological Therapy in Treating Patients With Lymphoma or Lymphoproliferative Disease				Phase II, Phase I				MSKCC-95024 NCI-V95-0685, NCT00002663
	Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Mycosis Fungoides/Sezary Syndrome				Phase II, Phase I				NHLBI-02-H-0250 NCT00047060
	Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions				Phase II, Phase I				Derm 446 NCT00129415
	Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas				Phase II, Phase I				LYMNHL0014 80057, LYMNHL0014, NCT00185965, NIH, NCT00185965
	Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome				Phase II, Phase I				NU-05H8 NU-0310-101, LILLY-NU-05H8, NCT00369629
	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease				Phase II, Phase I				BCM-H-19386 BCM-FAB, H 19386, NCT00625144


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute